Wall St futures flat amid US-China trade jitters; bank earnings in focus
Investing.com - H.C. Wainwright has reiterated its Buy rating and $50.00 price target on Assembly Biosciences (NASDAQ:ASMB), whose shares have surged nearly 16% in the past week and are trading near their 52-week high of $28. The renewed confidence comes following the company’s presentation of interim data for its genital herpes treatment.
The biotechnology company presented detailed interim data for ABI-5366, its long-acting oral helicase-primase inhibitor for recurrent genital herpes, at the International Union Against Sexually Transmitted Infections Congress in Europe on October 10.
According to H.C. Wainwright, the presented data demonstrated highly potent antiviral activity, favorable tolerability, and a pharmacokinetic profile that supports both weekly and monthly dosing regimens.
The research firm views these results as an important validation of Assembly’s helicase-primase inhibitor platform and believes they reduce risk for the advancement of ABI-5366 into Phase 2 clinical trials.
Assembly Biosciences plans to move ABI-5366 into Phase 2 clinical trials by mid-2026, according to the research note from H.C. Wainwright.
In other recent news, Assembly Biosciences reported positive interim data from its Phase 1b clinical trial for ABI-5366, a candidate for treating recurrent genital herpes. The trial showed a significant reduction in HSV type 2 shedding rate and genital lesion rate among participants. Following these results, Guggenheim raised its price target for Assembly Biosciences to $39, maintaining a Buy rating, while H.C. Wainwright also gave the company a Buy rating with a $50 price target. Additionally, Citizens JMP initiated coverage with a Market Outperform rating, emphasizing the experience of Assembly’s team in antiviral drug development.
To further support its research programs, Assembly Biosciences announced a $130 million offering to fund its viral disease therapeutic development. The offering includes approximately 6.6 million shares and warrants, with shares priced at $19.60 each. This funding aims to bolster the company’s efforts in advancing treatments for diseases such as hepatitis D and herpes simplex virus. These developments highlight the company’s ongoing progress and investment in its antiviral pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.